Drug Profile
Hydroxypropyl betadex - ZyVersa Therapeutics
Alternative Names: 2-hydroxypropyl-β-cyclodextrin - ZyVersa Therapeutics; 2HPβCD - ZyVersa Therapeutics; Cholesterol Efflux Mediator™; HPβCD - ZyVersa Therapeutics; Hydroxypropyl beta cyclodextrin - ZyVersa Therapeutics; VAR 200; VAR 200-01; VAR 200-02; VAR 200-03; VAR 300; VAR 400Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator L&F Research
- Developer ZyVersa Therapeutics
- Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
- Mechanism of Action Binding agents; Cholesterol modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic nephropathies; Focal segmental glomerulosclerosis; Hereditary nephritis
Most Recent Events
- 21 Aug 2023 ZyVersa Therapeutics plans a phase IIa trial for Diabetic nephropathies in the first half of 2024
- 06 Jun 2023 European Patent Office issued “Notice of Intention to Grant” ZyVersa’s patent application
- 03 Apr 2023 ZyVersa Therapeutics plans a phase IIa trial for Focal segmental glomerulosclerosis in fourth quarter of 2023